RESUMO
RNA tumor viruses and viruslike particles from human milk are quantitated by hybridization of the polyadenylic acid regions in their 60S to 70S RNA to radioactive polyribouridylic acid of known specific activity. The length of the polyadenylic acid region in the 60S to 70S RNA of the human milk particle is identical to that of the known oncogenic RNA viruses.
Assuntos
Leite Humano/microbiologia , Hibridização de Ácido Nucleico , Vírus Oncogênicos/isolamento & purificação , Polinucleotídeos/metabolismo , Vírus de RNA/isolamento & purificação , RNA Viral/metabolismo , Vírus da Leucose Aviária/metabolismo , Eletroforese em Gel de Poliacrilamida , Humanos , Peso Molecular , Poli U/metabolismo , Polinucleotídeos/análise , Vírus de RNA/metabolismo , RNA Viral/análise , Retroviridae/isolamento & purificação , TrítioRESUMO
Heterogeneity in the expression of tumor-associated antigens, as defined by the binding of monoclonal antibodies, is a characteristic common to most, if not all, human carcinoma cell populations. Antigen-negative cells within the population can escape detection and therapy by their failure to bind the appropriate antibody. Therefore, the extent of antigenic heterogeneity is an important consideration when designing protocols for the management of cancer by administration of monoclonal antibodies. One approach to counteracting the effect of antigenic heterogeneity is the use of clone A of recombinant human leukocyte interferon (Hu-IFN-alpha A). Administration of Hu-IFN-alpha A in vivo effectively increased the amount of tumor antigen expressed by a human colon xenograft in situ and augmented the localization of a radiolabeled monoclonal antibody to the tumor site. Concomitant administration of Hu-IFN-alpha A and monoclonal antibody may thus be effective in overcoming the antigenic heterogeneity of carcinoma cell populations and in enhancing the efficacy of monoclonal antibodies in the detection and treatment of carcinoma lesions.
Assuntos
Anticorpos Monoclonais/administração & dosagem , Antígenos de Neoplasias/imunologia , Carcinoma/imunologia , Neoplasias do Colo/imunologia , Interferon Tipo I/administração & dosagem , Animais , Antígenos de Superfície/imunologia , Antígenos HLA/imunologia , Humanos , Camundongos , Camundongos Nus , Transplante de NeoplasiasRESUMO
Primary mammary tumor cultures of RIII, GR, DD, BALB/c, and BALB/cfC3H mice were examined for mouse mammary tumor virus (MuMTV) production. Levels of production of 12-32 mug virus protein/day/75-cm2 culture flask could be maintained for 30-50 days with daily virus harvests. The viruses from tumor cell cultures of these mouse strains contained DNA polymerase with a strong preference for Mg++ over Mn++ as the divalent cation, a characteristic of DNA polymerase of MuMTV from mouse milk. These viruses from tumor cell cultures were excellent sources of MuMTV 3H-complementary DNA (complexed to 60-70S RNA) and radioactive 60-70S RNA, sufficiently free of contaminating murine leukemia virus nucleic acids, that can be used in molecular hybridization experiments. The effects of several culture parameters on MuMTV production were also studied.
Assuntos
Células Cultivadas , DNA Viral/análise , Magnésio , Vírus do Tumor Mamário do Camundongo/análise , Vírus do Tumor Mamário do Camundongo/crescimento & desenvolvimento , Manganês , RNA Viral/análise , Proteínas Virais/análiseRESUMO
Monoclonal antibody (MAb) B72.3 IgG was radiolabeled with 131I and administered to female athymic NCr-nu mice bearing the LS-174T human colon adenocarcinoma xenograft to determine if fractionation of MAb dose had any advantage in tumor therapy. In the LS-174T xenograft, only approximately 30%-60% of tumor cells express the B72.3-reactive TAG-72 antigen. The LS-174T xenograft was used to reflect the heterogeneity of the TAG-72 antigen often seen in biopsy specimens from patients. In contrast to a single 600-muCi dose of 131I-B72.3 IgG where 60% of the animals died from toxic effects, two 300-muCi doses of 131I-B72.3 IgG (total of 600 muCi) reduced or eliminated tumor growth in 90% of mice, with only 10% of the animals dying from toxic effects. Dose fractionation even permitted escalation of the dose to three doses (each 1 wk apart) of 300 muCi of 131I-B72.3 IgG (for a total of 900 muCi), resulting in even more extensive tumor reduction or elimination and minimal toxic effects. The use of an isotype-matched control MAb revealed a nonspecific component to tumor growth retardation, but the use of the specific B72.3 IgG demonstrated a much greater therapeutic effect. Tumors that had escaped MAb therapy were analyzed for expression of the B72.3-reactive TAG-72 antigen with the use of the immunoperoxidase method; they were shown to have the same antigenic phenotype as the untreated tumors. We verified tumor elimination by killing the test animals after a 7-week observation period and performing histologic examination of tumor sites. We also monitored toxic effects by histologic examination of numerous organs, including bone marrow. These studies thus demonstrate the advantage of dose fractionation of a radiolabeled MAb for tumor therapy. We anticipate that the concept of dose fractionation can be practically applied in radioimmunotherapeutic clinical trials with the development and use of recombinant-chimeric MAbs and modified constructs.
Assuntos
Anticorpos Monoclonais/administração & dosagem , Radioisótopos do Iodo/administração & dosagem , Neoplasias Experimentais/terapia , Animais , Anticorpos Monoclonais/efeitos adversos , Antígenos de Neoplasias/análise , Doenças da Medula Óssea/etiologia , Feminino , Glicoproteínas/análise , Humanos , Técnicas Imunoenzimáticas , Imunoglobulina G/administração & dosagem , Radioisótopos do Iodo/efeitos adversos , Camundongos , Camundongos Nus , Transplante de Neoplasias , Neoplasias Experimentais/imunologia , Neoplasias Experimentais/patologiaRESUMO
We describe here the first in vivo targeting of tumors with a single-chain antigen-binding protein. The molecule, which was constructed and expressed in Escherichia coli, is a novel recombinant protein composed of a variable light-chain (VL), amino acid sequence of an immunoglobulin tethered to a variable heavy-chain (VH) sequence by a designed peptide. We show that this protein, derived from the DNA sequence of the variable regions of the antitumor monoclonal antibody B6.2, has the same in vitro antigen-binding properties as the B6.2 Fab' fragment. Comparative pharmacokinetic studies in athymic mice demonstrate much more rapid alpha and beta phases of plasma clearance for the single-chain antigen-binding protein than for the Fab' fragment, as well as an extremely rapid whole-body clearance. Half-life values for alpha and beta phases of single-chain antigen-binding protein clearance were 2.4 minutes and 2.8 hours, respectively, versus 14.8 minutes and 7.5 hours for Fab'. Furthermore, the single-chain antigen-binding protein molecule did not show accumulation in the kidney as did the Fab' molecule or, as previously shown, the F(ab')2 molecule. Despite its rapid clearance, the single-chain antigen-binding protein showed uptake in a human tumor xenograft comparable to that of the Fab' fragment, resulting in tumor to normal tissue ratios comparable to or greater than those obtained with the Fab' fragment. These studies thus demonstrate the in vivo stability of recombinant single-chain antigen-binding proteins and their potential in some diagnostic and therapeutic clinical applications in cancer and other diseases.
Assuntos
Carcinoma/metabolismo , Proteínas de Transporte/farmacocinética , Neoplasias do Colo/metabolismo , Imunotoxinas/farmacocinética , Sequência de Aminoácidos , Animais , Proteínas de Transporte/uso terapêutico , Feminino , Meia-Vida , Humanos , Fragmentos Fab das Imunoglobulinas/administração & dosagem , Fragmentos Fab das Imunoglobulinas/farmacocinética , Imunotoxinas/genética , Imunotoxinas/uso terapêutico , Rim/metabolismo , Camundongos , Camundongos Nus , Dados de Sequência Molecular , Proteínas Recombinantes/genética , Proteínas Recombinantes/farmacocinética , Proteínas Recombinantes/uso terapêutico , Distribuição TecidualRESUMO
We have shown previously that approximately 20% of the Mason-Pfizer virus (MPV) genome is present as endogenous provirus in rhesus monkeys. We report here that several full-term rhesus placentas examined contain additional MPV proviral sequences in their DNA. Competitive molecular hybridization experiments demonstrated that some of these placentas also contain RNA complementary to the entire MPV 60 to 70S RNA genome. Examination of internal organs of rhesus monkeys captured in the wild also revealed the presence of additional MPV proviral sequences and expression of MPV RNA in some tissues. These results provide further evidence that MPV is being transmitted via a non-germ line mechanism in the rhesus population and now demonstrate the placenta as a good source for the identification of retrovirus transcriptional products and proviral DNA.
Assuntos
Macaca mulatta/microbiologia , Macaca/microbiologia , Vírus Oncogênicos/isolamento & purificação , Placenta/microbiologia , Vírus de RNA/isolamento & purificação , RNA Viral/isolamento & purificação , Animais , DNA Viral/isolamento & purificação , Feminino , Haplorrinos , Hibridização de Ácido Nucleico , Gravidez , Viroses/transmissãoRESUMO
Murine monoclonal antibodies, prepared against human metastatic mammary tumor cells, were used to demonstrate differential expression of several tumor-associated antigens (TAAs) among various mammary carcinomas and within a given tumor mass. Using the immunoperoxidase technique on serial sections of 39 human primary mammary carcinomas, a spectrum of antigenic phenotypes of TAAs was observed: 13% of the tumors reacted with all of a panel of four monoclonal antibodies; while 10% of the mammary tumors scored negative with all four antibodies. The remaining 30 tumors could be divided into several additional groups based on their differential reactivity with some, but not all, of the monoclonal antibodies. Furthermore, variation among mammary carcinomas was also observed in the cellular localization of antigens. Antigenic phenotypic diversity of mammary tumor cell populations within a given tumor mass was also observed; this was noted with respect to (a) antigenic expression in one area of a tumor mass and not another and (b) a "patchwork" effect in which antigens were expressed on cells immediately adjacent to cells which scored negative. Antigenic phenotypic diversity was also observed in established mammary tumor cell lines grown in vitro. A differential loss of some cell surface TAAs was observed as a function of continued cell passage; consistent with this finding, MCF-7 mammary tumor cell lines obtained from four sources could be differentiated from each other by their pattern of cell surface TAA expression. Single-cell clones derived from the MCF-7 mammary tumor cell line exhibited at least four distinct antigenic phenotypes; a change in cell surface phenotype of some of the clones was seen during subsequent passage. This definition of phenotypic variation and modulation of TAA expression among, and within, human mammary carcinomas has implications towards both the design and the outcome of studies involving the in situ immunodetection and therapy of breast cancer.
Assuntos
Adenocarcinoma/imunologia , Anticorpos Monoclonais , Antígenos de Neoplasias/análise , Neoplasias da Mama/imunologia , Animais , Linhagem Celular , Feminino , Humanos , Hibridomas/imunologia , Neoplasias Hepáticas/imunologia , Neoplasias Hepáticas/secundário , Linfócitos/imunologia , Camundongos , PlasmocitomaRESUMO
Monoclonal antibody B6.2 reacts with a protein found on the surface of primary and metastatic human mammary tumors. B6.2 immunoglobulin G (IgG) was purified, F(ab')2 and Fab' fragments were generated by pepsin digestion, and the IgG and its fragments were radiolabeled with 125I; all were successful in localizing human mammary tumors transplanted into athymic mice, with tumor:tissue ratios increasing over a 4-day period. The 125I-labeled IgG gave tumor:spleen, tumor:liver, and tumor:kidney ratios of greater than 10:1 and tumor:brain and tumor:muscle ratios of 50:1 to 110:1. The F(ab')2 fragment gave higher tumor:tissue ratios than did the IgG, with tumor:liver and tumor:spleen ratios of 15:1 to 20:1. No localization of the labeled B6.2 monoclonal antibody or its fragments was observed in athymic mice bearing a human melanoma or with isotype-identical control immunoglobulin or its fragments in athymic mice bearing the mammary tumors. Imaging experiments confirmed the ability of radiolabeled monoclonal antibody B6.2 and its fragments to detect the presence of transplanted human mammary tumor lesions of less than 0.4 cm without the aid of background subtraction manipulations.
Assuntos
Anticorpos Monoclonais , Antígenos de Neoplasias/análise , Neoplasias da Mama/imunologia , Animais , Feminino , Humanos , Fragmentos Fab das Imunoglobulinas , Imunoglobulina G , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Nus , Transplante de Neoplasias , Radioimunoensaio , Transplante HeterólogoRESUMO
Monoclonal antibodies have been generated against disrupted mammary tumor viruses isolated from Mus musculus, Mus cervicolor, and Mus cookii. Monoclonal antibodies directed against the M.W. 36,000 external glycoproteins of these viruses demonstrate the presence of multiple epitopes, i.e., distinct antigenic determinants, within these glycoproteins. These epitopes represent type, group, and interspecies determinants. Monoclonal antibodies have also been used to define multiple epitopes on the M.W. 28,000 major internal polypeptides of murine mammary tumor viruses that exhibit both type- and group-specific determinants. The monoclonal antibodies to the M.W. 36,000 glycoprotein and the M.W. 28,000 polypeptide have been used to distinguish all six mammary tumor virus isolates of M. musculus from each other, including both endogenous and exogenous viruses from the same strain, and a new virus isolate from BALB/c mice. With the use of the immunoperoxidase technique, the monoclonal antibodies generated have been used to demonstrate a heterogeneity of expression of mammary tumor virus gene products in primary mammary tumors of three Mus species. These studies have revealed that a given antigenic determinant may be expressed differentially in mammary tumors of two different Mus species, among mammary tumors of the same Mus species, and, at times, in different areas of the same mammary tumor.
Assuntos
Anticorpos , Gammaretrovirus/imunologia , Neoplasias Mamárias Experimentais/imunologia , Proteínas Virais/imunologia , Animais , Anticorpos Monoclonais , Anticorpos Antineoplásicos/imunologia , Anticorpos Antivirais/análise , Anticorpos Antivirais/imunologia , Epitopos/imunologia , Genes Virais , Camundongos , Camundongos Endogâmicos BALB C , Transplante de Neoplasias , Peptídeos/imunologia , Ratos , Especificidade da Espécie , Vírion/imunologiaRESUMO
Monoclonal antibody B72.3 binds to a glycoprotein complex with a molecular weight of 220,000 to 400,000. B72.3 reacts with approximately 50% of human mammary carcinomas and to 80% of the colon carcinomas tested but does not react appreciably with normal mammary tissue, with normal colon, or to a variety of normal adult human tissues tested using immunohistochemical techniques. B72.3 immunoglobulin G was purified and radiolabeled with 125I without significant loss in its reactivity to tumor extracts. The radiolabeled B72.3 immunoglobulin G was shown to efficiently localize human colon carcinoma xenografts in athymic mice. Tumor:tissue ratios of the localized antibody rose over the 7-day period studied, with tumor:liver, tumor:spleen, or tumor:kidney ratios of approximately 18:1 at Day 7 and a tumor:blood ratio of approximately 5:1 at Day 7. Tumor:muscle or tumor:brain ratios rose to over 100:1. The amount of radioactivity in the tumor increased for the first 2 days postinoculation of antibody and stayed constant over a 19-day period of study. Thus, there was no appreciable loss of radioiodine from the tumor over the study interval. No localization was seen in mice bearing a B72.3 antigen-negative human melanoma xenograft or with an isotype-identical control immunoglobulin G in mice bearing colon tumor xenografts. Gamma camera imaging with a pinhole collimator confirmed the ability of the radiolabeled antibody to detect the presence of colon carcinoma xenografts less than 0.5 cm in diameter over a 19-day period. The potential use of this system as a model for radioimmunotherapy will be discussed.
Assuntos
Antígenos de Neoplasias/análise , Neoplasias do Colo/imunologia , Animais , Anticorpos Monoclonais/isolamento & purificação , Linhagem Celular , Neoplasias do Colo/diagnóstico por imagem , Eletroforese em Gel de Poliacrilamida , Feminino , Glicoproteínas/análise , Humanos , Radioisótopos do Iodo , Camundongos , Camundongos Nus , Transplante de Neoplasias , Radioimunoensaio/métodos , Cintilografia , Transplante HeterólogoRESUMO
The effect of the relative affinity (Ka) on the antitumor efficacy of monoclonal antibodies (MAbs) has been questioned. It has previously been shown in experimental models that the use of MAbs with higher relative Kas manifests itself in a higher percentage of injected dose of MAb bound to tumor. On the other hand, mathematical models have proposed that the use of higher affinity MAbs may be disadvantageous for antitumor effects, since higher Ka MAbs would bind more antigen and prevent penetration of MAb through tumor. To test this hypothesis, three MAbs reacting to the human pancarcinoma antigen TAG-72 were used as radioimmunoconjugates for therapeutic efficacy versus the LS-174T human colon carcinoma xenograft. MAbs B72.3, CC49, and CC83 have all been shown by depletion studies to react to the same molecule and to all react with overlapping epitopes. While the relative Ka of B72.3 is 2.5 x 10(9) M-1, the relative Kas of CC49 and CC83 are 16.2 and 27.7 x 10(9) M-1, respectively. Each MAb was radiolabeled with 131I, and each radioimmunoconjugate was assayed at five dose levels for therapeutic efficacy using the human xenograft model. The results of these studies demonstrate substantial therapeutic advantage of the higher affinity MAbs CC49 and CC83 versus B72.3 at every dose level. While 500 microCi of B72.3 were required to reduce tumor growth in only a minority of tumor-bearing animals, the use of the same amount or less of the radioimmunoconjugates of CC49 or CC83 resulted in strong antitumor effects in 80 to 100% of tumor-bearing animals. Thus, stronger antitumor effects were seen using as little as 2.5- to 3-fold less of the higher Ka immunoconjugates CC49 and CC83 as compared with B72.3. While we acknowledge the potential disadvantages of higher Ka MAbs in some situations, at least the experimental studies and model system described here show that a distinct therapeutic advantage exists with the use of higher affinity immunoconjugates.
Assuntos
Adenocarcinoma Mucinoso/radioterapia , Anticorpos Monoclonais/uso terapêutico , Neoplasias do Colo/radioterapia , Imunoglobulina G/uso terapêutico , Radioisótopos do Iodo/uso terapêutico , Radioimunoterapia/métodos , Animais , Afinidade de Anticorpos , Antígenos de Neoplasias/imunologia , Feminino , Glicoproteínas/imunologia , Humanos , Camundongos , Camundongos Nus , Dosagem Radioterapêutica , Células Tumorais CultivadasRESUMO
The B72.3 reactive antigen, TAG-72, has been purified and a series of second generation monoclonal antibodies (MAbs), designated CC (colon cancer), have been characterized by a range of in vitro immunological assays. Six CC MAbs (CC11, CC30, CC46, CC49, CC83, and CC92) were chosen for analyses of the in vivo binding to a human colon carcinoma xenograft. All 6 MAbs were previously shown to be distinct from B72.3 and each other by a series of reciprocal competition radio-immunoassays, and all were shown to have a Ka higher than that of B72.3. In this study we demonstrate that all six CC MAbs evaluated are superior to B72.3 in an in vivo tumor targeting model, using human colon carcinoma (LS-174T) xenografts in athymic mice, in terms of both the percentage of the injected dose of radiolabeled MAb delivered per g of tumor and tumor:normal tissue ratios. Differences in the in vivo binding patterns and pharmacokinetics among the CC MAbs are also evaluated. Thus, in light of the fact that B72.3 has been shown to successfully target approximately 75% of primary and metastatic carcinoma lesions in a variety of different carcinoma types in over 300 patients, these studies serve as further evidence to support the clinical evaluation of the second generation CC MAbs, either alone or in combination with B72.3.
Assuntos
Anticorpos Monoclonais , Antígenos de Neoplasias/imunologia , Neoplasias Experimentais/diagnóstico , Animais , Anticorpos Monoclonais/análise , Anticorpos Monoclonais/isolamento & purificação , Especificidade de Anticorpos , Neoplasias do Colo/imunologia , Humanos , Radioisótopos do Iodo , Camundongos , Camundongos Endogâmicos BALB C , Transplante de Neoplasias , Neoplasias Experimentais/imunologia , Transplante HeterólogoRESUMO
Monoclonal antibody B72.3 was generated using a membrane-enriched fraction of cells from a mammary carcinoma metastasis and has been shown previously to have a high degree of selective reactivity for human breast and colon carcinoma versus normal adult tissues. The reactive antigen has been shown to be a high-molecular-weight glycoprotein complex of approximately 220,000 to 400,000 and is termed tumor-associated glycoprotein 72 (TAG-72). We report here a dichotomy in the expression of TAG-72 in carcinoma biopsy material versus carcinoma cell lines. While 44% (25 of 56) of human breast carcinoma and 80% (16 of 20) of colon carcinoma biopsies express TAG-72 as assayed by radioimmunoassay or immunohistochemistry, only one of 25 breast cancer cell lines [MCF-7 (one variant)] and one of 18 colon cancer cell lines (LS-174T) express this antigen. Furthermore, TAG-72 expression in these two cell lines was shown to be a property of a low percentage of cells within each culture. Attempts to enhance TAG-72 expression in LS-174T cells by propagation on extracellular matrix proteins, such as collagen, laminin, and fibronectin, or in serum-containing or serum-free, hormone-supplemented medium proved unsuccessful. A pronounced increase in TAG-72 expression was observed, however, when the LS-174T cells were grown under culture conditions which promote three-dimensional growth. LS-174T cells grown in spheroid or suspension cultures demonstrated a 2- to 7-fold increase in TAG-72 antigen expression, while those grown on agar plugs demonstrated a 10-fold increase. When the LS-174T cell line was injected into athymic mice to generate tumors, the level of TAG-72 antigen increased over 100-fold, to levels comparable to those seen in the metastatic tumor masses from patients. Thus, spatial configuration of carcinoma cell populations is shown to influence the expression of a tumor-associated antigen and the subsequent surface binding of monoclonal antibody B72.3. The implications of these findings in the potential utility of monoclonal antibodies for the in vivo detection and destruction of carcinoma masses are discussed.
Assuntos
Anticorpos Monoclonais , Neoplasias da Mama/análise , Neoplasias do Colo/análise , Glicoproteínas/análise , Antígenos de Superfície/análise , Biópsia , Neoplasias da Mama/ultraestrutura , Linhagem Celular , Neoplasias do Colo/ultraestrutura , Feminino , Humanos , Técnicas Imunoenzimáticas , RadioimunoensaioRESUMO
Thirteen patients with metastatic breast carcinoma were given injections of 50-1593 micrograms of 131I-monoclonal antibody (MAb) B6.2 immunoglobulin G and F(ab')2 for pharmacokinetic evaluation and radioimmunoimaging. Blood clearance of the 131I-MAb-B6.2 was biphasic. The mean half-times (t 1/2 alpha, t 1/2 beta) for the immunoglobulin G were 3.5 +/- 1.7 and 20.9 +/- 11.0 h, respectively. The t 1/2 alpha for the F(ab')2 was 1.7 +/- 1.3 h, and the t 1/2 beta was 31.0 +/- 5.7 h. The percentage of protein bound 131I for the immunoglobulin G and for the F(ab')2 at 72 h was 73.7 +/- 11.4% and 58.2 +/- 14.5%, respectively. In vitro reactivity of MAb B6.2 with granulocytes isolated from normal subjects and patients was demonstrated by cytofluorometric and radioimmunoassays. MAb B6.2 was shown to bind with normal cross-reacting antigen, a cell surface antigen known to be expressed on normal human granulocytes. Reactivity with normal cross-reacting antigen on granulocytes is consistent with the skeletal images obtained during immunoscintigraphy of all 13 patients. A specific tumor image was observed in one patient. No toxicity was encountered. In spite of extensive preclinical data suggesting that 131I-MAb B6.2 would be a useful agent for radioimmunoimaging, the clinical utility of this reagent is probably limited because of the reactivity with granulocytes.
Assuntos
Anticorpos Monoclonais , Neoplasias da Mama/metabolismo , Adulto , Idoso , Animais , Neoplasias da Mama/diagnóstico por imagem , Neoplasias da Mama/imunologia , Reações Cruzadas , Feminino , Granulócitos/imunologia , Meia-Vida , Humanos , Fragmentos Fab das Imunoglobulinas , Imunoglobulina G/metabolismo , Radioisótopos do Iodo , Cinética , Camundongos , Camundongos Endogâmicos BALB C , Pessoa de Meia-Idade , Metástase Neoplásica , CintilografiaRESUMO
Murine monoclonal antibodies (MAbs) reactive with distinct epitopes on carcinoembryonic antigen (CEA) have been analyzed systematically by radioimmunoassays, Western blotting, and immunohistochemical assays to define CEA expression in adenocarcinomas, benign lesions, and normal tissues of the stomach. Each of four COL-MAbs (COL-1, COL-4, COL-6, and COL-12) reacted preferentially with cell extracts of adenocarcinomas versus those of normal mucosae in solid-phase radioimmunoassays. Using Western blotting analyses MAbs COL-1, COL-4, COL-6, and COL-12 detected only the Mr 180,000 molecule characteristic of CEA in adenocarcinoma of the stomach; no reactivity was observed in an extract of normal gastric mucosa. Antibody competition radioimmunoassays were then carried out to define relations among COL-MAbs using 125I-radiolabeled MAbs, and nonradiolabeled MAbs as competitors. A spectrum of formalin-fixed, paraffin-embedded normal, benign, and malignant tissue sections of the stomach were examined for immunoreactivities with COL-MAbs using immunohistochemical assays to define whether the COL-MAbs were able to detect CEA expression in early foci of gastric carcinomas. All of the COL-MAbs generally demonstrated selective reactivities to adenocarcinomas (n = 40) versus benign lesions (n = 15) and normal mucosae (n = 6) of the stomach. From 72 to 100% of adenocarcinomas at early stage (n = 18) were reactive with the COL-MAbs, suggesting that these MAbs might serve as immunohistochemical diagnostic tools to detect early foci of gastric carcinoma. The data reported here indicate that the COL-MAbs can potentially be utilized as radioimmunological and immunohistochemical adjuncts to differentiate early adenocarcinomas from normal mucosae or benign lesions of the stomach on the basis of differential CEA expression.
Assuntos
Adenocarcinoma/imunologia , Anticorpos Monoclonais/imunologia , Antígeno Carcinoembrionário/imunologia , Gastropatias/imunologia , Neoplasias Gástricas/imunologia , Adenocarcinoma/diagnóstico , Especificidade de Anticorpos , Fixadores , Congelamento , Mucosa Gástrica/imunologia , Humanos , Técnicas de Imunoadsorção , Radioimunoensaio , Neoplasias Gástricas/diagnósticoRESUMO
Monoclonal antibody B72.3 binds a high-molecular-weight tumor-associated glycoprotein identified as TAG-72. This study reports the partial purification and characterization of TAG-72 from a xenograft of a human carcinoma cell line, LS-174T, which expresses high levels of this antigen. The tumor homogenate was initially fractionated by Sepharose CL-4B chromatography. The high-molecular-weight TAG-72, found in the exclusion volume, was then subjected to two sequential passages through B72.3 antibody affinity columns. At each step of the procedure, TAG-72 content was quantitated using a competition radioimmunoassay, and the degree of purification was expressed as the ratio of antigen in units to total protein. The three-step procedure produced a purification of TAG-72 with minimal contamination by other proteins as shown by polyacrylamide gel electrophoresis, followed by staining with Coomassie Blue or periodic acid/Schiff reagent. The density of affinity-purified TAG-72, as determined by cesium chloride gradient ultracentrifugation, was found to be 1.45 g/ml. This density determination, together with the high molecular weight of TAG-72, its resistance to Chondroitinase digestion, the presence of blood group-related oligosaccharides, and sensitivity to shearing into lower-molecular-weight forms suggest that TAG-72 is a mucin-like molecule.
Assuntos
Antígenos de Neoplasias/isolamento & purificação , Glicoproteínas/isolamento & purificação , Mucinas/isolamento & purificação , Proteínas de Neoplasias/isolamento & purificação , Anticorpos Monoclonais , Antígenos de Neoplasias/imunologia , Antígenos de Grupos Sanguíneos , Sequência de Carboidratos , Citoplasma/imunologia , Eletroforese em Gel de Poliacrilamida , Glicoproteínas/imunologia , Humanos , Peso Molecular , Mucinas/imunologia , Proteínas de Neoplasias/imunologia , UltracentrifugaçãoRESUMO
Failure of radiolabeled monoclonal antibodies (MAbs) in the treatment of solid tumors, for the most part, is a result of undesirable pharmacokinetics that lead to significant radiation exposure of normal tissues and an inadequate delivery of radiation doses to tumors. Using genetic engineering, antitumor MAbs can be optimized for desirable clinical applications. In the present study, we report the generation of a tetravalent single-chain Fv [[sc(Fv)2]2] of the murine MAb CC49 that recognizes the tumor-associated glycoprotein, TAG-72. [Sc(Fv)2]2 was expressed as a secreted soluble protein in Pichia pastoris under the regulation of alcohol oxidase 1 promoter. The in vitro binding properties of the tetravalent construct were analyzed by solid-phase RIA and surface plasmon resonance studies using BIAcore. The binding affinity constant (K(A)) for the [sc(Fv)2]2 and CC49 IgG were similar, i.e., 1.02 x 10(8) M(-1) and 1.14 x 10(8) M(-1), respectively, and were 4-fold higher than its divalent scFv [sc(Fv)2; 2.75 x 10(7) M(-1)]. At 6 h postadministration, the percentage of injected dose accumulated/g of LS-174T colon carcinoma xenografts was 21.3+/-1.3, 9.8+/-1.3, and 17.3+/-1.1 for radioiodinated [sc(Fv)2]2, sc(Fv)2, and IgG, respectively. Pharmacokinetic analysis of blood clearance studies showed the elimination half-life for [sc(Fv)2]2, sc(Fv)2, and IgG as 170, 80, and 330 min, respectively. The gain in avidity resulting from multivalency along with an improved biological half-life makes the tetravalent construct an important reagent for cancer therapy and diagnosis in MAb-based radiopharmaceuticals.
Assuntos
Anticorpos Antineoplásicos/genética , Anticorpos Antineoplásicos/uso terapêutico , Antineoplásicos/farmacocinética , Antineoplásicos/uso terapêutico , Oxirredutases do Álcool/genética , Sequência de Aminoácidos , Animais , Cromatografia Líquida de Alta Pressão , Neoplasias do Colo/tratamento farmacológico , Neoplasias do Colo/imunologia , Eletroforese em Gel de Poliacrilamida , Feminino , Engenharia Genética , Vetores Genéticos , Imunoglobulina G/sangue , Camundongos , Camundongos Nus , Modelos Biológicos , Dados de Sequência Molecular , Transplante de Neoplasias , Pichia/metabolismo , Regiões Promotoras Genéticas , Ligação Proteica , Radioimunoensaio , Homologia de Sequência de Aminoácidos , Ressonância de Plasmônio de Superfície , Fatores de Tempo , Distribuição TecidualRESUMO
Monoclonal antibody (MAb) B72.3 has been shown to be of potential utility in the management of human carcinoma via its use in (a) the targeting of carcinoma lesions in colorectal and ovarian cancer patients, (b) immunohistochemical analyses of biopsies and effusions, and (c) serum assays to help define the presence of carcinoma. The B72.3-reactive antigen, designated tumor-associated glycoprotein 72 (TAG-72), has been characterized as a high molecular weight glycoprotein with the properties of a mucin. We report here the utilization of MAb B72.3 and 18 second generation MAbs (generated using purified TAG-72 obtained from a colon carcinoma xenograft as immunogen) to construct a serological map of the TAG-72 molecule. The generation and initial characterization of 10 of the second generation MAbs have been described previously; in addition, eight previously unreported MAbs were used. All 19 MAbs produced immune precipitate lines against purified TAG-72 in double immunodiffusion, indicating that each epitope recognized by a single MAb is present at least twice on the TAG-72 molecule. Immunodepletion analyses utilizing 11 of the anti-TAG-72 MAbs indicated that each recognizes the same molecule or population of molecules. Nineteen competition radioimmunoassays were developed and 19 purified competitor immunoglobulins were used in each assay. The patterns of cross-competition indicated the presence of a complex array of tumor-associated epitopes on the TAG-72 molecule. Some of the MAbs recognized epitopes that were structurally or spatially related to one another, but none appeared to recognize identical epitopes. The spectrum of inhibitory reactivities of these MAbs for TAG-72 binding varied from extremely restricted to more broad inhibition. The serological mapping studies reported here provide information as to the range and nature of the epitopes expressed on the TAG-72 molecule, help form the basis for selecting alternative anti-TAG-72 MAbs for use in potential clinical applications, and further define the nature of this oncofetal antigen.
Assuntos
Anticorpos Monoclonais , Antígenos de Neoplasias/análise , Neoplasias do Colo/patologia , Glicoproteínas/análise , Neoplasias Ovarianas/patologia , Anticorpos Monoclonais/isolamento & purificação , Antígenos de Neoplasias/imunologia , Antígenos de Neoplasias/isolamento & purificação , Western Blotting , Antígeno Carcinoembrionário/isolamento & purificação , Linhagem Celular , Neoplasias do Colo/análise , Ensaio de Imunoadsorção Enzimática , Epitopos/análise , Feminino , Glicoproteínas/imunologia , Glicoproteínas/isolamento & purificação , Humanos , Técnicas Imunoenzimáticas , Neoplasias Ovarianas/análise , RadioimunoensaioRESUMO
Mouse mammary tumor viruses (MMTV) from three different strains of mice have been used to establish productive infections in feline and mink cell lines. The virions that are released by these cells compete completely in a radioimmunoassay for the major virion surface glycoprotein of MMTV (gp52), thus demonstrating that antigenic determinants of gp52 are viral coded. Competitive molecular hybridization studies have shown that the 60 to 70 S RNA's of MMTV's propagated in feline cells contain all the nucleic acid sequences found in 60 to 70 S RNA from MMTV synthesized by murine cells. The virion buoyant densities in sucrose and cesium chloride, virion sedimentation coefficient, divalent cation requirement of the virion DNA polymerase, and morphology of MMTV's synthesized in heterologous cells are similar to those of MMTV's grown in murine cells. Cultures of MMTV-infected feline cells have continuously released between 0.1 and 1.0 microgram of virus per 10(7) cells (75-sq cm flask) per day during the 60-week observation period. No detectable feline or murine type C viruses were produced by these cultures.
Assuntos
Transformação Celular Neoplásica , Vírus do Tumor Mamário do Camundongo , Animais , Antígenos Virais , Cátions Bivalentes , Gatos , Membrana Celular/microbiologia , Membrana Celular/ultraestrutura , Células Cultivadas , DNA Viral/análise , DNA Polimerase Dirigida por DNA/metabolismo , Epitopos , Glicoproteínas/análise , Glicoproteínas/imunologia , Corpos de Inclusão Viral , Vírus do Tumor Mamário do Camundongo/enzimologia , Vírus do Tumor Mamário do Camundongo/isolamento & purificação , Camundongos , Vison , Hibridização de Ácido Nucleico , RNA Viral/análise , Especificidade da Espécie , Proteínas Virais/análise , Proteínas Virais/imunologia , Replicação ViralRESUMO
The cell surface-binding properties of two murine monoclonal antibodies reactive with human mammary tumor cells are described. Fluorescence-activated cell sorter analyses demonstrate that both monoclonal antibodies, B6.2 and B38.1, are reactive with the surface of the majority of human breast tumor cell lines tested but are unreactive with a variety of normal human cell lines, melanomas, sarcomas, and lymphoid tumors. Antibody B6.2 was also reactive with selective carcinomas, while antibody B38.1 showed even broader reactivity. The two monoclonal antibodies were unreactive with the surface of a variety of normal human tissues obtained at biopsy, including lymph nodes, bone marrow, and spleen, but were reactive with mammary tumor cells obtained from four of six pleural effusions. Surface binding to mammary tumor cells by both monoclonal antibodies was shown to decrease during density-dependent arrest; further cell cycle analysis demonstrated differential antibody surface binding during S phase. Prolonged exposure of mammary tumor cells to antibody showed no evidence of antigen capping or internalization. Both monoclonal antibodies were shown to lyse mammary tumor cells in antibody-dependent cell-mediated cytotoxicity.